Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
07:00am, Monday, 14'th Jul 2025
CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseas
Agios Appoints Dr. Jay Backstrom to Board of Directors
07:00am, Tuesday, 08'th Jul 2025
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseas
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders
08:40am, Monday, 09'th Jun 2025
AMSTERDAM--(BUSINESS WIRE)-- #biotech--Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to p
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
07:00am, Wednesday, 28'th May 2025
Agios Pharmaceuticals, Inc. announced that its management team is scheduled to present at the Goldman Sachs Healthcare Conference on June 9 at 8:40 a.m. ET
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
10:00am, Wednesday, 14'th May 2025
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare disease
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
07:00am, Friday, 09'th May 2025
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates
08:55am, Friday, 02'nd May 2025
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
07:00am, Friday, 02'nd May 2025
CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced
Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript
12:06pm, Thursday, 01'st May 2025
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Chris Taylor – Vice President-Investor Relations and Corporate Communications
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
08:50am, Thursday, 01'st May 2025
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.55 per share versus the Zacks Consensus Estimate of a loss of $1.80. This compares to loss of $1.45 per share a year ago.
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
06:30am, Thursday, 01'st May 2025
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
11:05am, Thursday, 24'th Apr 2025
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025
07:00am, Thursday, 17'th Apr 2025
CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare disea
New Strong Sell Stocks for April 8th
07:25am, Tuesday, 08'th Apr 2025
AFLYY, AGIO and ARLP have been added to the Zacks Rank #5 (Strong Sell) List on April 8, 2025.
New Strong Sell Stocks for April 3rd
04:55am, Thursday, 03'rd Apr 2025
AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025.
